We previously found that bortezomib induced apoptosis in triple-negative (negative expression of ER, PR and HER2) breast cancer cells through downregulation of CIP2A and p-Akt, suggesting that CIP2A is a target of bortezomib [25]. Here, ESR1 is linked to breast carcinoma.